CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin

Holly R Keir; Hollian Richardson; Christina Fillmore; Amelia Shoemark; Aili L Lazaar; Bruce E Miller; Ruth Tal-Singer; James D Chalmers; Divya Mohan

doi:10.1183/23120541.00583-2020

CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin

ERJ Open Res. 2020 Nov 10;6(4):00583-2020. doi: 10.1183/23120541.00583-2020. eCollection 2020 Oct.

Authors

Holly R Keir¹, Hollian Richardson¹, Christina Fillmore², Amelia Shoemark¹, Aili L Lazaar³, Bruce E Miller³, Ruth Tal-Singer³, James D Chalmers¹, Divya Mohan³

Affiliations

¹ Ninewells Clinical Research Centre, University of Dundee, Dundee, UK.
² GSK R&D, Stevenage, UK.
³ GSK R&D, Collegeville, PA, USA.

Abstract

The implications of these findings are significant for development of CXCR2 antagonists and other mechanisms targeting neutrophil activation or NETosis, suggesting that IL-8-dependent mechanisms will only work in a subset of COPD patients https://bit.ly/32SeisO.